News about Market

Life Couriers Completes Acquisition by JLL Partners

Life Couriers completes its acquisition by JLL Partners and appoints healthcare logistics executive Edward DeMartini as CEO to drive growth and expansion.

Market | 19/08/2026 | By News Bureau

Piramal Pharma Acquires 40.67 Percent Additional Stake in Yapan Bio for INR 76 Crore

Piramal Pharma acquires an additional 40.67 percent stake in Yapan Bio for INR 76 crore, raising its ownership to 74 percent and expanding its biologics Contract Development and Manufacturing Organisation (CDMO) capabilities.

Market | 18/08/2026 | By News Bureau |  105

OmniAb and Eli Lilly Partner on Ion Channel Program

OmniAb and Eli Lilly enter a global collaboration for an ion channel program, leveraging OmniAb’s technology platform and expertise in ion channel discovery and screening.

Market | 17/08/2026 | By News Bureau |  110

Pharming Launches Joenja in Japan for APDS Patients Aged 4 and Older

Pharming has launched Joenja in Japan for APDS patients aged 4 years and older, making Japan the first market to offer the treatment commercially to children aged 4–11.

Market | 14/08/2026 | By News Bureau |  100

Tris Pharma Partners with Calm Health, ADHD Central to Expand Support for ADHD Patients

Tris Pharma has partnered with Calm Health and ADHD Central to complement ADHD treatment with mental wellness, organisation and productivity resources for patients and caregivers.

Market | 14/08/2026 | By News Bureau

Tasman Therapeutics and Osmind Partner to Advance R-107 for Depressive Disorders

Tasman Therapeutics and Osmind are partnering to advance R-107, an investigational oral extended-release ketamine therapy, through phase 3 trials for depressive disorders.

Market | 13/08/2026 | By News Bureau

Zealand Pharma Signs USD 100 Million Royalty Deal with Royalty Pharma for Rusfertide

Zealand Pharma will receive USD 100 million from Royalty Pharma for its rusfertide economic interests, unlocking value from royalty rights for strategic investments.

Market | 13/08/2026 | By News Bureau |  127

CellProthera and Alfresa Sign MOU to Advance ProtheraCytes Phase 3 in Japan

CellProthera and Alfresa Holdings have signed a Memorandum of Understanding (MOU) to advance ProtheraCytes phase 3 development and future wholesale distribution in Japan for severe myocardial infarction.

Market | 13/08/2026 | By News Bureau

Sentynl and Mereo Partner on Alvelestat for AATD-Associated Lung Disease

Sentynl Therapeutics and Mereo BioPharma have signed an option and license deal for alvelestat, with Sentynl set to commercialise it in the US upon option exercise.

Market | 12/08/2026 | By News Bureau

Jazz Pharmaceuticals to Acquire Actio Biosciences for USD 1.32 Billion to Advance Rare Epilepsy Therapy

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for USD 820 million upfront and up to USD 500 million in contingent payments, expanding its rare epilepsy pipeline with investigational therapy ABS-1230.

Market | 12/08/2026 | By News Bureau